Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
(NASDAQ: VKTX) reported completion of enrollment in its phase 3 VANQUISH-2 trial evaluating VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity treatment
typical oral doses range 250500 mg daily, though some protocols use up to 1,000 mg divided doses
A major cause of CVD is atherosclerosis, a chronic inflammatory disease characterized by the pathogenic accumulation of vascular smooth muscle cells (VSMC), oxidized lipids and immune cells in the artery wall 2,3,4
They need to treat it as an unknown unlicensed injection rather than as confirmed retatrutide, because nobody can verify what was in it
It is not, however, FDA-approved as an anti-inflammatory medication the anti-inflammatory effects are a documented benefit, not its primary indication
So, you eat fewer calories, resulting in weight loss
